Regeneron Pharmaceuticals Inc (REGN) : Eqis Capital Management reduced its stake in Regeneron Pharmaceuticals Inc by 2.13% during the most recent quarter end. The investment management company now holds a total of 4,458 shares of Regeneron Pharmaceuticals Inc which is valued at $1,750,211 after selling 97 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Oct 4, 2016.Regeneron Pharmaceuticals Inc makes up approximately 0.11% of Eqis Capital Management’s portfolio.
Other Hedge Funds, Including , Washington Trust Bank added REGN to its portfolio by purchasing 12 company shares during the most recent quarter which is valued at $4,711.
Regeneron Pharmaceuticals Inc closed down -5.62 points or -1.40% at $397.2 with 5,58,306 shares getting traded on Tuesday. Post opening the session at $403.82, the shares hit an intraday low of $394.55 and an intraday high of $406 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.